Loading…

Assessment of the feed additive consisting of Lacticaseibacillus paracasei NCIMB 30151 for all animal species for the renewal of its authorisation (Microferm ltd.)

Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of a preparation of Lacticaseibacillus paracasei NCIMB 30151 as a technological additive to improve ensiling of fresh material for all an...

Full description

Saved in:
Bibliographic Details
Published in:EFSA journal 2024-11, Vol.22 (11), p.e9074-n/a
Main Authors: Villa, Roberto Edoardo, Azimonti, Giovanna, Bonos, Eleftherios, Christensen, Henrik, Durjava, Mojca, Dusemund, Birgit, Gehring, Ronette, Glandorf, Boet, Kouba, Maryline, López‐Alonso, Marta, Marcon, Francesca, Nebbia, Carlo, Pechová, Alena, Prieto‐Maradona, Miguel, Röhe, Ilen, Theodoridou, Katerina, Anguita, Montserrat, Bozzi Cionci, Nicole, Galobart, Jaume, Innocenti, Matteo L., Revez, Joana
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of a preparation of Lacticaseibacillus paracasei NCIMB 30151 as a technological additive to improve ensiling of fresh material for all animal species. The applicant has provided evidence that the additive currently on the market complies with the existing conditions of authorisation. There was no new evidence that would lead to the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) to reconsider its previous conclusions for all animal species, consumers and the environment, for which the additive is considered to remain safe. Regarding user safety, the panel concluded that L. paracasei NCIMB 30151 should be considered a skin and respiratory sensitiser, and any exposure through the skin and respiratory tract is considered a risk. In the absence of data, no conclusion could be drawn on the eye irritation potential of the additive. There is no need for assessing the efficacy of the additive in the context of renewal of the authorisation.
ISSN:1831-4732
1831-4732
2314-9396
DOI:10.2903/j.efsa.2024.9074